Sagent aids Nichi-Iko with sales and profit
A¥27.2 billion (US$249 million) contribution from Sagent carried Japan’s Nichi-Iko to sales growth of more than a fifth in the first nine months of its financial year ending 31 March 2018. However, the Japanese player is trading behind its full-year financial forecast, and also saw its operating margin dip during the nine months ended 31 December 2017.
You may also be interested in...
Japan’s Towa has struck a deal to acquire the Pensa Investments generics division of Spain’s Esteve in an all-cash transaction worth €320m. The acquisition gives Towa access to the Spanish market as well as subsidiaries in Europe and the US.
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.